Journal article

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

Adriana Baz Morelli, Dorit Becher, Sandra Koernig, Anabel Silva, Debbie Drane, Eugene Maraskovsky

JOURNAL OF MEDICAL MICROBIOLOGY | MICROBIOLOGY SOC | Published : 2012

Abstract

The ISCOMATRIX adjuvant has antigen delivery and presentation properties as well as immunomodulatory capabilities, which combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as CD4(+) and CD8(+) T-cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have now been tested in clinical trials and have been shown to be generally safe and well tolerated as well as immunogenic, generating both antibody (Ab) and T-cell responses. The mechanisms by which ISCOMATRIX adjuvant facilitates its immune effects are the scope of significant study and indicate that ISCOMATRIX adjuvant (i) rapid..

View full abstract

University of Melbourne Researchers